Home / Encyclopedia / Khavinson Bioregulators / Testagen

MONOGRAPH No. 062

EVIDENCE BASELimited

TYPE

Synthetic tetrapeptide bioregulator

SEQUENCE

Lys-Glu-Asp-Gly

CAS

Not assigned

EU STATUS

Research only

WADA

Not listed

MIN PURITY

≥98% HPLC

Khavinson Bioregulators

Testagen — EU research guide.

Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator series, proposed to support testosterone synthesis. It is studied in hypogonadism-related models as part of the same research family as Prostamax.

Last reviewed: 2026-09-24

What is Testagen?

What does the research show?

Available data are limited to one small clinical report (36 patients) and computational modelling; no animal study of the peptide was found. No independently replicated controlled human trial data is publicly available as of mid-2026, in contrast to established hormonal-axis compounds like Gonadorelin.

EU legal status

Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.

⚠ Should not be confused with clinically established testosterone-axis therapies — this is preliminary bioregulator research with a narrow evidence base, not a validated hormonal treatment.

✓ PeptideCompare monitors Testagen across EU research suppliers. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.

EVIDENCE SUMMARY

LIMITED

Testosterone in androgen deficiency with chronic prostatitis (one small report) — A 2011 report in Problems of Endocrine Pathology followed 36 patients with chronic abacterial prostatitis (type IIIA) and androgen deficiency for one month of conservative therapy that included Testagen, and describes better uroflowmetry, less prostatic inflammation and higher serum total testosterone. The abstract names no placebo group, so the contribution of the peptide cannot be separated, and no independent replication was found.

LIMITED

Proposed mechanism: DNA binding (in silico only) — A 2016 paper from the Khavinson group lists Testagen as the tetrapeptide Lys-Glu-Asp-Gly and predicts, by molecular docking, strong binding (roughly -4 to -4.5 kcal/mol) to a complementary DNA sequence. This is a computational model, not an experimental result, and it does not show an effect on the pituitary or on testosterone.

Molecular information

Molecular formula

C17H29N5O9

Molecular weight

447.4 g/mol

CAS number

Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C

36+ mo

Stable · >95% potency

Fridge 4 °C

3-4 mo

In use · after recon

Room 20 °C

10-13 days

Limited · moderate loss

Warm 37 °C+

2-3 days

Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Testagen is not yet in our price comparison

We expand EU supplier coverage every month.

References

Small clinical report of 36 patients over one month, published in a Ukrainian endocrinology journal. Only the abstract could be read: it gives no placebo group and does not state the peptide sequence, so it cannot show that the peptide caused the changes. Rossikhin VV, Hoshchenko YuO, Osipov PG. Efficacy of testosterone synthesis inductor application Testagen in androgenic deficiency in patients with chronic abacterial prostatitis. Problems of Endocrine Pathology. 2011;36(2):17-22. DOI
Modelling paper by the Khavinson group that ties the name Testagen to the sequence Lys-Glu-Asp-Gly. It is a docking prediction only, with no laboratory or clinical data on Testagen. Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. DOI

Testagen — EU research guide.

What is Testagen?

What does the research show?

EU legal status

Molecular information

Pharmacokinetics

Potency retained over time

Testagen is not yet in our price comparison

References

Related guides

Bolamin

Bronchogen

Cardiogen